The Role of Psychedelics and Counseling in Mental Health Treatment
Journal of Mental Health Counseling – October 01, 2020
Source: OpenAlex
Summary
After centuries of global use and decades of restriction (1950s-1970s), psychedelic-assisted therapy is transforming psychiatry. Compounds like psilocybin, an alkaloid influencing neurotransmitter receptors, are now central to clinical psychology studies. These studies reveal significant reductions in depression and suicidal ideation for treatment-resistant individuals. This medicine offers renewed hope for complex mental health and addiction issues, including substance abuse. Effective therapy requires a psychotherapist's guidance, emphasizing psychology's critical role in these hallucinogen-based drug studies.
Abstract
Psychedelics (i.e., ketamine, methylenedioxymethamphetamine, psilocybin) have been effectively used globally for centuries to treat mental health and addiction issues. However, in the 1950s–1970s, a number of factors, including misuse, abuse, and poorly conceptualized and conducted clinical trials, caused the Federal Drug Administration to classify most of the psychedelic substances as having no medical value. Now, however, recent research is indicating that psychedelic-assisted therapy can significantly reduce depression and suicidal ideation in treatment-resistant clients, and it may be efficacious in treating other mental health and addiction issues as well. Researchers have also identified the critical therapeutic components that ensure effective psychedelic-assisted therapy, not least the need for mental health counseling before, during, and after treatment. The purpose of this manuscript is to share the latest psychedelic therapy research and to discuss how mental health counselors can contribute to this reemerging therapeutic trend.